Description

ABSTRACT

Aim: To compare the safety and efficacy profile of uroselective alpha-1 blocker-Alfuzosin in comparison to an alpha-1A receptor subtype specific antagonist-Tamsulosin in Benign Prostatic Hyperplasia. Materials and Methods: A prospective, open labelled, alternative randomised, single centred study in a tertiary hospital where the patient visiting Urology department with diagnosis of Benign Prostatic Hyperplasia (BPH). The data include demographics data like patient ID, age of the patient, dates of visiting to the OPD and other details like history of presenting illness etc. An approved proforma was administered to patients enlisting vital signs like blood pressure, heart rate, systemic examination like cardiovascular system and abdomen examination including digital per rectal examination. Laboratory investigations included RBS, prostate specific antigen and urine analysis. The ultrasonography investigations were done to measure the size of the prostate and post void residual urine. The uroflow meter analysis was done as an OPD procedure to assess the amount of urine voided during urination. Results: In our study, patients receiving Tamsulosin 0.4mg once daily and Alfuzosin 10 mg once daily showed a significant improvement in post void residual urine, uroflow rates and symptoms at 1st and 3rd months. The improvement in the above parameters was found to be statistically insignificant between the two groups. The adverse effects like headache, fatigue and dizziness were reported in both the groups. Conclusion: The improvement in the treatment of benign prostatic hyperplasia with tamsulosin 0.4mg once daily and alfuzosin 10 mg once daily was similar.

Keywords: Tamsulosin, Alfuzosin, Benign prostatic hyperplasia, Post void residual urine